Skip to content
by Legal Desire
13 January 2026

Latham Advises on Arrowhead Pharmaceuticals Upsized Offerings of US$625 Million Convertible Senior Notes, and US$200 Million Common Stock and Pre-Funded Warrants

Advising firms

Deal team

15 lawyers named
LawyerFirmSeniorityPracticeOffice
Matt Bush Lead Latham & Watkins LLP Partner Capital Markets San Diego
Greg Rodgers Lead Latham & Watkins LLP Partner Capital Markets New York
Arash Aminian Baghai Lead Latham & Watkins LLP Partner Capital Markets Los Angeles
Anthony Gostanian Latham & Watkins LLP Counsel Capital Markets San Diego
Andrew Bentz Latham & Watkins LLP Associate Capital Markets Not stated
Omeed Valipour Latham & Watkins LLP Associate Capital Markets Not stated
Sterling Swift Latham & Watkins LLP Associate Capital Markets Not stated
Steve Hess Latham & Watkins LLP Associate Capital Markets Not stated
Ariana Alemi Latham & Watkins LLP Associate Capital Markets Not stated
Catherine Lee Latham & Watkins LLP Partner derivatives New York
Christopher Yu Latham & Watkins LLP Counsel derivatives Not stated
Adam Zhang Latham & Watkins LLP Associate derivatives Not stated
Rebecca Kientz Latham & Watkins LLP Not stated derivatives Not stated
Elena Romanova Latham & Watkins LLP Partner tax New York
Jack Santoro Latham & Watkins LLP Associate tax Not stated

Stated terms

Stated value
USD 625m (US$625 million)
What the figure measures
Issue size
Client
Arrowhead Pharmaceuticals, Inc.Issuer
Counterparties
Not stated